5-Hyroxymethylcytosine Immunohistochemical Staining Correlates with Overall Survival in Patients with Chronic Myelomonocytic Leukemia by Selove, William et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2016 UMass Center for Clinical and 
Translational Science Research Retreat 
May 20th, 12:30 PM 
5-Hyroxymethylcytosine Immunohistochemical Staining 
Correlates with Overall Survival in Patients with Chronic 
Myelomonocytic Leukemia 
William Selove 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the Neoplasms Commons, and the Pathology Commons 
Selove W, Dresser KA, Chen B. (2016). 5-Hyroxymethylcytosine Immunohistochemical Staining Correlates 
with Overall Survival in Patients with Chronic Myelomonocytic Leukemia. UMass Center for Clinical and 
Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/
2016/posters/76 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
5-Hyroxymethylcytosine Immunohistochemical Staining Correlates with Overall Survival 
in Patients with Chronic Myelomonocytic Leukemia 
William Selove, MD , Karen Dresser BS,HT(ASCP), Benjamin J. Chen MD, PhD 
UMass Medical School, Dept of Pathology, Worcester, MA 
Introduction 
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm 
that has been associated with a number of genetic mutations, most commonly TET2 mutations 
in up to 50-60% of cases.  Mutations in epigenetic genes such as TET2 are known to disrupt the 
conversion of 5-methycytosine to 5-hydroxymethylcytosine (5hmC), contributing to oncogenesis.    
We hypothesized that CMML cases would exhibit decreased 5hmC expression, reflecting the 
propensity for TET2 mutations in CMML.  We also sought to determine whether 5hmC IHC 
status reflected disease severity in terms of progression to AML and overall patient survival.   
Methods 
Thirty-five cases of CMML from between 1/2006 and 12/2014 were identified from the pathology 
archives at UMass, under an IRB-approved protocol.  IHC was performed on FFPE bone 
marrow biopsy specimens with an anti-5hmC antibody.  Staining was scored based on intensity 
of nuclear staining: 0 (neg) to 3+ (strong); and proportion of cells staining: 0 (<1%), 1 (1-25%), 2 
(26-50%), 3 (51-75%), 4 (>76%).  A combined product score was calculated yielding scores of 
0-12.  Correlation to clinical parameters (age, blast count, progression to AML, and overall 
patient survival) was investigated.   
Results 
60% (21/35) of CMML cases showed low expression of 5hmc (combined score <=4).  This loss 
of 5hmC expression correlated significantly with poorer overall survival in Kaplan-Meier curves 
(p=0.0287).  There was no significant correlation between 5hmC score and patient age, blast 
count, or AML progression.    
Conclusion 
IHC detection of 5hmC in CMML is significantly correlated with patient overall survival and could 
potentially be utilized as a prognostic biomarker.  Loss of 5hmC expression likely reflects 
mutations to epigenetic pathways and could be useful in guiding treatment with hypomethylating 
agents. 
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